Brief: Fibrobiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial Evaluating Cywc628 For The Treatment Of Diabetic Foot Ulcers
03/06/2026 12:26
BRIEF-Fibrobiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial Evaluating Cywc628 For The Treatment Of Diabetic Foot Ulcers June 3 (Reuters) - Fibrobiologics Inc FBLG.O:
FIBROBIOLOGICS ANNOUNCES FIRST PATIENTS DOSED IN PHASE 1/2 CLINICAL TRIAL EVALUATING CYWC628 FOR THE TREATMENT OF DIABETIC FOOT ULCERS
Source text: ID:nGNXGwWql
Further company coverage: FBLG.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts